US 9522163

Here's a concise summary of US Patent 9522163:

Title: Methods of treating hepatitis

Assignee: Yale University and University of Pittsburgh

Inventors: Leo E. Otterbein, Augustine M. K. Choi, Brian Scott Zuckerbraun

Filing Date: December 2, 2013

Issue Date: December 20, 2016

Abstract: The invention describes a method for treating hepatitis in a patient by administering a pharmaceutical composition containing carbon monoxide.

Legal Status: Expired - Fee Related (Anticipated expiration: May 16, 2023).

CAFC 2026 Dockets: A search of CAFC 2026 dockets for patent number 9522163 did not yield any specific results.

Plain-Language Overview of Independent Claims:

• Claim 1: This claim describes a method for treating, preventing, or reducing the risk of hepatitis in a patient. It involves identifying a patient with or at risk for hepatitis and then giving them a medicine that contains enough carbon monoxide to be effective against the hepatitis.
• Claim 11: This claim outlines a method for treating or preventing hepatitis by exposing a patient to an atmosphere containing carbon monoxide gas. This atmosphere is created by releasing pressurized carbon monoxide gas from a container, and the amount of carbon monoxide in this atmosphere is sufficient to treat the hepatitis.
• Claim 13: This claim details a method for performing abdominal surgery, such as a liver transplant, on a patient where hepatitis is a potential risk. It involves identifying such a patient, performing the surgery, and at some point before, during, or after the surgery, having the patient inhale enough carbon monoxide gas to reduce the risk of hepatitis.
• Claim 15: This claim focuses on treating hepatitis in a patient where the hepatitis is not caused by surgery or bacterial endotoxin. The method involves identifying such a patient and administering a pharmaceutical composition containing an effective amount of carbon monoxide to treat the hepatitis.
• Claim 17: This claim describes a method for administering a drug that can cause hepatitis (a hepatotoxic drug) to a patient. It includes giving the patient the drug and, concurrently or at some point before or after, also administering a carbon monoxide-containing pharmaceutical composition in an amount effective to treat hepatitis.
• Claim 19: This claim describes a vessel (container) that holds medical-grade compressed carbon monoxide gas. This vessel must have a label indicating that the gas can be used to treat hepatitis in a patient.
• Claim 20: This claim describes a vessel (container) that holds medical-grade compressed carbon monoxide gas. This vessel must have a label indicating that the gas can be given to a patient along with a drug known to induce hepatitis.